Lecture Series: Toward Personalized Medicine in Schizophrenia: Clinical Trials Targeting Specific Biomarkers and Patient Populations

While significant advances in schizophrenia treatment have occurred, novel treatments have been slow to advance to the clinic.  The disease construct is broad and may consist of several distinct disease pathways suggesting that targeted treatments and personalized medicine may be important and a critical consideration in drug development. This talk will discuss the concept of target of engagement and treatment targets to link to disease outcomes and how this strategy may lead to drug development. Within this framework, she will focus on a few lines of work that involve modulation and measurement of the immune system, inflammation, and oxidative stress. Rationale and clinical trial design will be discussed as well as the concept of personalized medicine.

Join Zoom Meeting
https://umd.zoom.us/j/91339482909?pwd=Y3hwWXdYMnp2MTU0dFhLWGxJZllIdz09

Meeting ID: 913 3948 2909
Passcode: 712542

One tap mobile
+13017158592,,91339482909# US (Washington DC)
+19294362866,,91339482909# US (New York)

Dial by your location
        +1 301 715 8592 US (Washington DC)
        +1 929 436 2866 US (New York)
        +1 312 626 6799 US (Chicago)
        +1 253 215 8782 US (Tacoma)
        +1 346 248 7799 US (Houston)
        +1 669 900 6833 US (San Jose)

Meeting ID: 913 3948 2909

Find your local number: https://umd.zoom.us/u/ab5NeTlwno